A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.

[1]  G. Banfi,et al.  Tenofovir and Bone: Age-Dependent Effects in a Zebrafish Animal Model , 2016, Antiviral therapy.

[2]  C. Fichtenbaum,et al.  Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  L. Aurpibul,et al.  Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing , 2015, The Pediatric infectious disease journal.

[4]  J. Pinto,et al.  Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy: The Final Results of Study GS-US-104–0321 , 2015, The Pediatric infectious disease journal.

[5]  K. Squires,et al.  Bone Health and Human Immunodeficiency Virus Infection , 2013, Pharmacotherapy.

[6]  R. Luiz,et al.  Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[7]  J. Gathe,et al.  Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. , 2012, AIDS research and human retroviruses.

[8]  K. White,et al.  A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents , 2012, The Pediatric infectious disease journal.

[9]  P. Sax,et al.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.

[10]  V. Fabiano,et al.  Tenofovir Disoproxil Fumarate and Bone Mineral Density: A 60-Month Longitudinal Study in a Cohort of H V -Infected Youths , 2010, Antiviral therapy.

[11]  D. Ward,et al.  Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients , 2009, Journal of acquired immune deficiency syndromes.

[12]  S. Zeichner,et al.  Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. , 2008, The Journal of pediatrics.

[13]  John D Seeger,et al.  Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Cheng,et al.  The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients , 2007, HIV clinical trials.

[15]  S. Zeichner,et al.  Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children , 2006, Pediatrics.

[16]  E. Spada,et al.  Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr) , 2006, Journal of endocrinological investigation.

[17]  S. Mora,et al.  A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children , 2005, Journal of acquired immune deficiency syndromes.

[18]  S. Steinberg,et al.  Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection , 2005, Pediatrics.

[19]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[20]  V. Gilsanz,et al.  Establishment of peak bone mass. , 2003, Endocrinology and metabolism clinics of North America.

[21]  C. Gordon,et al.  Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD Pediatric Official Positions. , 2014, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[22]  C. Gordon,et al.  Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.